Baby KJ Muldoon Takes First Steps After 1st Personalized In Vivo CRISPR for CPS1 Deficiency
Updated
Updated · Bored Panda · May 14
Baby KJ Muldoon Takes First Steps After 1st Personalized In Vivo CRISPR for CPS1 Deficiency
5 articles · Updated · Bored Panda · May 14
18-month-old KJ Muldoon reached a milestone once thought unlikely—taking his first steps after becoming the first patient to receive a personalized in vivo CRISPR treatment for CPS1 deficiency.
Within days of his birth, doctors diagnosed the rare disorder, which blocks the liver from converting toxic ammonia into urea and can cause severe brain and liver damage without intervention.
Over six months, researchers at Children’s Hospital of Philadelphia designed and refined a custom gene-editing therapy tailored to KJ’s specific mutation.
After treatment, KJ’s blood ammonia fell to safe levels, letting him tolerate dietary protein, reduce medication and gain weight instead of remaining hospitalized while awaiting a liver transplant.
The case marks an early proof of concept for bespoke gene-editing therapies that could be built rapidly for rare genetic diseases previously considered treatable only with organ transplantation.
How might AI-driven rare disease diagnosis reshape healthcare access and equity worldwide?
What unforeseen consequences could arise from engineering self-healing materials and new sensory experiences like the color 'Olo'?
Could resurrecting extinct species like dire wolves disrupt ecosystems or create risks we haven't anticipated?
The First Personalized CRISPR Cure for CPS1 Deficiency: Lessons from KJ Muldoon's Case and the Future of Precision Medicine
Overview
CPS1 deficiency is a severe metabolic disorder that causes serious health challenges, such as trouble tolerating protein and keeping ammonia levels stable. Traditional treatments often fail to prevent health crises. Recently, a personalized CRISPR therapy was given to KJ Muldoon, who received the first infusion in early 2026. After treatment, KJ’s health improved greatly, including better protein tolerance. This breakthrough shows the potential of precise gene editing to help patients with hard-to-treat conditions, offering hope for more effective solutions where standard care falls short.